These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8697160)

  • 1. Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.
    Davidson NC; Coutie WJ; Webb DJ; Struthers AD
    Heart; 1996 Jun; 75(6):576-81. PubMed ID: 8697160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
    Sigurdsson A
    Blood Press Suppl; 1995; 1():1-45. PubMed ID: 7599749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of angiotensin converting enzyme inhibitor with different doses on plasma brain natriuretic peptide and norepinephrine in patients with chronic heart failure].
    Song HM; Zhang J; Deng B; Luo M
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(25):1737-40. PubMed ID: 16253158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in plasma cardiac natriuretic peptides concentrations during 1 year treatment with angiotensin-converting enzyme inhibitor in elderly hypertensive patients with left ventricular hypertrophy.
    Kohno M; Yokokawa K; Yasunari K; Kano H; Minami M; Hanehira T; Yoshikawa J
    Int J Clin Pharmacol Ther; 1997 Jan; 35(1):38-42. PubMed ID: 9021441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction.
    Wald DS; Law M; Mills S; Bestwick JP; Morris JK; Wald NJ
    Clin Ther; 2008 Nov; 30(11):2030-9. PubMed ID: 19108791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow-up.
    Eveson DJ; Robinson TG; Potter JF
    Am J Hypertens; 2007 Mar; 20(3):270-7. PubMed ID: 17324738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial.
    Rydén L; Armstrong PW; Cleland JG; Horowitz JD; Massie BM; Packer M; Poole-Wilson PA
    Eur Heart J; 2000 Dec; 21(23):1967-78. PubMed ID: 11071803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic, hormonal, and renal actions of adrenomedullin 2 in experimental heart failure.
    Rademaker MT; Charles CJ; Nicholls MG; Richards AM
    Circ Heart Fail; 2008 Jul; 1(2):134-42. PubMed ID: 19808282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular and renal effects of low-dose atrial natriuretic peptide in compensated cirrhosis.
    La Villa G; Lazzeri C; Pascale A; Sestini S; Bisi G; Sciagrà R; Vecchiarino S; Raggi VC; Barletta G; Laffi G; Gentilini P
    Am J Gastroenterol; 1997 May; 92(5):852-7. PubMed ID: 9149200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hemodynamic and humoral effects of parenteral therapy with intravenously administered ACE inhibitor quinaprilat in patients with advanced heart failure].
    Mitrovic V; Mudra H; Bonzel T; Schmidt W; Schlepper M
    Z Kardiol; 1996 Nov; 85(11):828-38. PubMed ID: 9064945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Acute changes in the hemodynamic profile and circulating levels of atrial natriuretic peptide induced by dobutamine in severe heart failure].
    La Vecchia L; Bottero M; Centofante P; Bedogni F; Ometto R; Cera A; Fortunato A
    G Ital Cardiol; 1996 Aug; 26(8):863-74. PubMed ID: 9005168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic and renal effects of atrial natriuretic peptide in patients with heart failure treated with angiotensin-converting enzyme inhibitor or in acute saline solution loading.
    Tomiyama H; Watanabe G; Abe M; Okazaki R; Yoshida H; Doba N
    Am Heart J; 2001 Mar; 141(3):422-7. PubMed ID: 11231440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenopril.
    Westendorp B; Schoemaker RG; van Gilst WH; van Veldhuisen DJ; Buikema H
    Eur J Pharmacol; 2005 Dec; 527(1-3):141-9. PubMed ID: 16310764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neurohumoral activation, regulation of sodium excretion and vasodilator treatment in heart insufficiency].
    Pimenta J; Pereira M; Castro A; Dias P; Azevedo A; Bettencourt P; Ferreira A
    Rev Port Cardiol; 2002 Feb; 21(2):157-62. PubMed ID: 11963285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-type natriuretic peptide in chronic renal failure and its action in humans.
    Igaki T; Itoh H; Suga S; Hama N; Ogawa Y; Komatsu Y; Mukoyama M; Sugawara A; Yoshimasa T; Tanaka I; Nakao K
    Kidney Int Suppl; 1996 Jun; 55():S144-7. PubMed ID: 8743538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.
    Wang DJ; Dowling TC; Meadows D; Ayala T; Marshall J; Minshall S; Greenberg N; Thattassery E; Fisher ML; Rao K; Gottlieb SS
    Circulation; 2004 Sep; 110(12):1620-5. PubMed ID: 15337695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
    McMurray JJ; Pitt B; Latini R; Maggioni AP; Solomon SD; Keefe DL; Ford J; Verma A; Lewsey J;
    Circ Heart Fail; 2008 May; 1(1):17-24. PubMed ID: 19808266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal response to candoxatrilat in patients with heart failure.
    Good JM; Peters M; Wilkins M; Jackson N; Oakley CM; Cleland JG
    J Am Coll Cardiol; 1995 May; 25(6):1273-81. PubMed ID: 7722120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
    Wallis EJ; Ramsay LE; Hettiarachchi J
    Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verapamil sustained-release in renal parenchymal hypertension: effect on blood pressure, kidney function, angiotensin II, aldosterone, arginine vasopressin, atrial natriuretic peptide, and lipoproteins.
    Eiskjaer H; Pedersen EB; Rasmussen LM; Jespersen B
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S17-22. PubMed ID: 2475677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.